| Ident. | Authors (with country if any) | Title |
|---|
| 003567 |
B. J. Snow [Canada] ; F. J. G. Vingerhoets [Canada] ; J. W. Langston [États-Unis] ; J. W. Tetrud [États-Unis] ; V. Sossi [Canada] ; D. B. Calne [Canada] | Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism |
| 003585 |
R. De La Fuente-Fernandez [Canada] ; P. K. Pal [Canada] ; F. J. G. Vingerhoets [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. K. Mak [Canada] ; T. J. Ruth [Canada] ; B. J. Snow [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations |
| 003593 |
P. K. Pal [Canada] ; D. B. Calne [Canada] ; S. Calne [Canada] ; J. K. C. Tsui [Canada] | Botulinum toxin A as treatment for drooling saliva in PD |
| 003718 |
A. Samii [Canada] ; I. M. Turnbull [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Reassessment of unilateral pallidotomy in Parkinson's disease |
| 003791 |
C. R. Honey [Canada] ; A. J. Stoessl [Canada] ; J. K. C. Tsui [Canada] ; M. Schulzer [Canada] ; D. B. Calne [Canada] | Unilateral pallidotomy for reduction of parkinsonian pain |
| 003810 |
A. Samii [Canada] ; K. Markopoulou [États-Unis] ; Z. K. Wszolek [États-Unis] ; V. Sossi [Canada] ; T. Dobko [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | PET studies of parkinsonism associated with mutation in the α-synuclein gene |
| 003811 |
J. K. C. Tsui [Canada] ; D. B. Calne [Canada] ; YUE WANG [Canada] ; M. Schulzer [Canada] ; S. A. Marion [Canada] | Occupational risk factors in Parkinson's disease |
| 003A31 |
C.-C. Huang [Taïwan] ; N.-S. Chu [Taïwan] ; C.-S. Lu [Taïwan] ; R.-S. Chen [Taïwan] ; D. B. Calne [Canada] | Long-term progression in chronic manganism : Ten years of follow-up |
| 003A37 |
M. D. Muenter [États-Unis] ; L. S. Forno [États-Unis] ; O. Hornykiewicz [Autriche] ; S. J. Kish [Canada] ; D. M. Maraganore [États-Unis] ; R. J. Caselli [États-Unis] ; H. Okazaki [États-Unis] ; F. M. Jr Howard [États-Unis] ; B. J. Snow [Australie] ; D. B. Calne [Canada] | Hereditary form of parkinsonism-dementia |
| 003C59 |
A. Kishore [Canada] ; I. M. Turnbull [Canada] ; B. J. Snow [Canada] ; R. De La Fuente-Fernandez [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: Six-month follow-up with additional 1-year observations |
| 003C78 |
R. J. Uitti [Canada] ; H. Shinotoh [Canada] ; M. Hayward [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] | "Familial Parkinson's disease": A case-control study of families |
| 004008 |
Konstantine K. Duarte [Espagne] ; L. E. Clavería ; J. De Pedro-Cuesta [Espagne, Suède] ; A. P. Sempere ; F. Coria ; D. B. Calne [Canada] | Screening Parkinson's disease: A validated questionnaire of high specificity and sensitivity |
| 004081 |
H. Shinotoh [Canada] ; D. B. Calne | The use of PET in Parkinson's disease |
| 004091 |
C. S. Lee [Canada] ; M. Schulzer ; E. Mak ; J. P. Hammerstad ; S. Calne ; D. B. Calne | Patterns of asymmetry do not change over the course of idiopathic parkinsonism : implications for pathogenesis |
| 004187 |
M. Schulzer [Canada] ; C. S. Lee [Canada] ; E. K. Mak [Canada] ; F. J. G. Vingerhoets [Canada] ; D. B. Calne [Canada] | A mathematical model of pathogenesis in idiopathic parkinsonism |
| 004207 |
J. P. Hammerstad [Canada] ; K. Elliott [Canada] ; E. Mak [Canada] ; M. Schulzer [Canada] ; S. Calne [Canada] ; D. B. Calne [Canada] | Tendon jerks in Parkinson's disease |
| 004243 |
F. J. G. Vingerhoets [Canada] ; F. J. G. Snow [Canada] ; C. S. Lee [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] | Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism |
| 004298 |
D. B. Calne [Canada] ; N.-S. Chu ; C.-C. Huang ; C.-S. Lu ; W. Olanow | Manganism and idiopathic parkinsonism : similarities and differences |
| 004300 |
D. B. Calne [Canada] | Is idiopathic parkinsonism the consequence of an event or a process ? |
| 004352 |
H. Takahashi [Canada] ; Bj Snow [Canada] ; M. H. Bhatt [Canada] ; R. Peppard [Canada] ; A. Eisen [Canada] ; D. B. Calne [Canada] | Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning |
| 004383 |
Michael Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] | Reply |
| 004401 |
B. J. Snow [Canada] ; I. Tooyama [Canada, Japon] ; I. Mcgeer [Canada] ; T. Yamada [Canada] ; D. B. Calne [Canada] ; H. Takahashi [Canada] ; H. Kimura [Japon] | Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels |
| 004405 |
T. Yamada [Canada] ; D. B. Calne [Canada] ; H. Akiyama [Japon] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Further observations on Tau-positive glia in the brains with progressive supranuclear palsy |
| 004419 |
Janice J. Pate [Canada] ; T. Kawamata [Canada] ; T. Yamada [Canada] ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices |
| 004432 |
D. B. Calne [Canada] | Treatment of Parkinson's disease |
| 004439 |
R. J. Uitti [Canada] ; D. B. Calne | Pathogenesis of idiopathic parkinsonism |
| 004442 |
D. B. Calne [Canada] ; B. J. Snow | PET imaging in parkinsonism |
| 004455 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
| 004457 |
H. Takahashi [Canada] ; B. J. Snow [Canada] ; T. G. Nygaard ; D. B. Calne [Canada] | Clinical heterogeneity of dopa-responsive dystonia : PET observations |
| 004549 |
James W. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 004555 |
D B Wszolek [États-Unis, Canada] ; R. F. Pfeiffer [États-Unis] ; M. H. Bhatt [Canada] ; R. L. Schelper [États-Unis] ; M. Cordes [Canada] ; B. J. Snow [Canada] ; R. L. Rodnitzky [États-Unis] ; E. Ch Wolters [Pays-Bas] ; F. Arwert [Pays-Bas] ; D. B. Calne [Canada] | Rapidly progressive autosomal dominant parkinsonism and dementia with pallido‐ponto‐nigral degeneration |
| 004624 |
D. B. Calne [Canada] | The nature of Pakinson's disease |
| 004625 |
D. B. Calne [Canada] | The free radical hypothesis in idiopathic Parkinsonism : evidence against it |
| 004628 |
M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 004655 |
D. B. Calne [Canada] ; B. J. Snow ; C. Lee | Criteria for diagnosing Parkinson's disease |
| 004657 |
R. F. Peppard [Canada] ; R. Wayne Martin [Canada] ; G. D. Carr ; E. Grochowski ; M. Schulzer [Canada] ; M. Guttman [Canada] ; P. L. Mcgeer ; A. G. Phillips ; J. K. C. Tsui [Canada] ; D. B. Calne [Canada] | Cerebral glucose metabolism in Parkinson's disease with and without dementia |
| 004664 |
M. Cordes [Canada] ; B. J. Snow ; H. Takahashi ; P. Schofield ; S. Cooper ; V. Sossi ; S. Morrison ; D. B. Calne | L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion |
| 004819 |
D. B. Calne [Canada] | Neurotoxins and degeneration in the central nervous system |
| 004829 |
D. B. Calne ; M. J. Zigmond | Compensatory mechanisms in degenerative neurologic diseases : insights from Parkinsonism |
| 004962 |
R. F. Peppard ; W. R. W. Martin [Canada] ; C. M. Clark ; G. D. Carr ; P. L. Mcgeer ; D. B. Calne | Cortical glucose metabolism in parkinson's and alzheimer's disease |
| 004987 |
M. H. Bhatt ; B. J. Snow ; W. R. W. Martin ; S. Cooper ; D. B. Calne | Positron emission tomography in Shy-Drager syndrome |
| 004993 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
| 004A02 |
J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
| 004A04 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
| 004A94 |
Richard L. Martin [Canada] ; M. R. Palmer [Canada] ; C. S. Patlak [États-Unis] ; D. B. Calne | Nigrostriatal function in humans studied with positron emission tomography |
| 004B25 |
VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
| 004B26 |
J. K. Tsui ; S. Ross ; K. Poulin ; J. Douglas ; D. Postnikoff ; S. Calne ; W. Woodward ; D. B. Calne | The effect of dietary protein on the efficacy of L-dopa: a double-blind study |
| 004B32 |
M. Guttman ; R. S. Burns ; W. R. W. Martin ; R. F. Peppard ; M. J. Adam ; T. J. Ruth ; G. Allen ; R. A. Parker ; N. B. Tulipan ; D. B. Calne | PET studies of Parkinsonian patients treated with autologous adrenal implants |
| 004B33 |
H. Teravainen ; J. K. C. Tsui ; E. Mak ; D. B. Calne | Optimal indices for testing parkinsonian rigidity |
| 004B38 |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
| 004B41 |
T. A. Cox ; J. V. Mcdarby ; L. Lavine ; J. C. Steele ; D. B. Calne | A retinopathy on Guam with high prevalence in Lytico-Bodig |
| 004B42 |
J. K. C. Tsui ; E. C. Wolters ; R. F. Peppard ; D. B. Calne | A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease |
| 004C39 |
M. Guttman [Canada] ; V. W. Yong [Canada] ; S. U. Kim [Canada] ; D. B. Calne [Canada] ; W. R. W. Martin [Canada] ; M. J. Adam [Canada] ; T. J. Ruth [Canada] | Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys |
| 004C47 |
T. A. Hurwitz ; D. B. Calne ; K. Waterman | Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy |
| 004C57 |
D. B. Calne ; A. J. Lees | Late progression of post encephalitic Parkinson's syndrome |
| 004C64 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 004D91 |
S. Calne ; B. Schoenberg ; W. Martin ; R. J. Uitti ; P. Spencer ; D. B. Calne | Familial Parkinson's disease: possible role of environmental factors |
| 004E93 |
H. Teravainen ; L. Forgach ; M. Hietanen ; M. Schulzer ; B. Schoenberg ; D. B. Calne | The age of onset of Parkinson's disease: etiological implications |
| 004E96 |
C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
| 004F03 |
E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
| 004F10 |
D. B. Calne ; E. Mcgeer ; A. Eisen ; P. Spencer | Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotropic interaction between ageing and environment? |
| 004F97 |
K. Burton [Canada] ; D. B. Calne [Canada] | Dopamine agonists and Parkinson's disease |
| 005032 |
T. A. Larsen ; R. Newman ; P. Lewitt ; D. B. Calne | Severity of Parkinsońs disease and the dosage of bromocriptine |
